Twist Bioscience (TWST) Jefferies Global Healthcare Conference summary

Strategic direction and growth

• Focused on scalable, profitable growth by targeting expanding markets and launching new products.

• Achieved significant revenue growth from $2.3M in 2016 to $245M in 2023, with Q2 2024 revenue at $75M and 41% gross margin.

• Guidance for fiscal 2024 is $300M–$304M in revenue, with a target of 50% gross margin by end of fiscal 2025.

• Efficient operations and a high fixed-cost, low variable-cost model improve margins as revenue scales.

• Cash management supports profitability goals, with $245M expected in the bank at year-end.

Technology and product innovation

• Proprietary silicon chip technology enables production of up to 16 million oligos per day and hundreds of thousands of genes per month.

• Miniaturization allows for cost, scale, and sustainability advantages over competitors.

• Expanded applications from DNA to RNA, proteins, and data storage.

• Platform supports hundreds of SKUs for diverse customer needs, all derived from the same chip.

• Sustainability advantage: gene synthesis emits far less carbon than competitors.

Product groups and market reach

• Four product groups: SynBio, NGS, Biopharma Solutions, and Data Storage.

• SynBio and NGS serve thousands of customers, mainly in healthcare, pharma, biotech, and diagnostics.

• Biopharma Solutions offers a differentiated service combining in vivo, in vitro, and AI for drug discovery.

• Data Storage group is developing DNA-based archival storage, targeting early commercial access in 2025.

• Large addressable markets remain, with significant growth potential in SynBio and NGS.